BCG immunotherapy of bladder cancer: 20 years on
- 1 May 1999
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 353 (9165), 1689-1694
- https://doi.org/10.1016/s0140-6736(98)07422-4
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Tumour immunology: false hopes—new horizons?Immunology Today, 1998
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Genetically Regulated Response to Intravesical Bacillus Calmette Guerin Immunotherapy of Orthotopic Murine Bladder TumorJournal of Urology, 1997
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- The Effect of Lubricants on Viability of Bacillus Calmette-Guerin for Intravesical Immunotherapy Against Bladder CarcinomaJournal of Urology, 1996
- Expression of mage genes in transitional‐cell carcinomas of the urinary bladderInternational Journal of Cancer, 1995
- The production of cytokines by polymorphonuclear neutrophilsImmunology Today, 1995
- Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells.JCI Insight, 1993
- Intravesical BCG: Current results, natural history and implicants for urothelial cancer preventionJournal of Cellular Biochemistry, 1992
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969